Omega-3 Fatty Acids for Hyperactivity Treatment in Autism Spectrum Disorder
Effectiveness of Omega-3 Fatty Acids for the Reduction of Hyperactivity in Children With Autism Spectrum Disorder
Sponsor: Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
This PHASE2 trial investigates Autism Spectrum Disorders and Hyperactivity and is currently completed. Hugo W. Moser Research Institute at Kennedy Krieger, Inc. leads this study, which shows 10 recorded versions since 2012 — indicating substantial longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE2
▶ Show 5 earlier versions
-
Sep 2020 — Jan 2021 [monthly]
Completed PHASE2
-
Jun 2018 — Sep 2020 [monthly]
Completed PHASE2
-
Apr 2018 — Jun 2018 [monthly]
Completed PHASE2
-
Feb 2017 — Apr 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Sep 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
- University of California, San Francisco
For direct contact, visit the study record on ClinicalTrials.gov .